Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.
Biotech Venture Limped Through 2025. A Brighter 2026 Beckons.
Get alerts for these topics
Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.